Marker Therapeutics, Inc.
MRKR
$1.42
-$0.04-2.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.55M | 4.70M | 5.39M | 5.70M | 6.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.55M | 4.70M | 5.39M | 5.70M | 6.59M |
| Cost of Revenue | 11.80M | 14.74M | 15.87M | 14.03M | 13.47M |
| Gross Profit | -8.25M | -10.05M | -10.48M | -8.33M | -6.88M |
| SG&A Expenses | 4.18M | 4.37M | 4.20M | 4.39M | 4.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.98M | 19.11M | 20.07M | 18.42M | 17.71M |
| Operating Income | -12.44M | -14.41M | -14.68M | -12.72M | -11.12M |
| Income Before Tax | -12.18M | -14.25M | -14.56M | -12.73M | -10.68M |
| Income Tax Expenses | -15.20K | 50.00K | 50.00K | 50.00K | 50.00K |
| Earnings from Continuing Operations | -12.16 | -14.30 | -14.61 | -12.78 | -10.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.16M | -14.30M | -14.61M | -12.78M | -10.73M |
| EBIT | -12.44M | -14.41M | -14.68M | -12.72M | -11.12M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.90 | -1.23 | -1.36 | -1.32 | -1.19 |
| Normalized Basic EPS | -0.53 | -0.74 | -0.82 | -0.80 | -0.74 |
| EPS Diluted | -0.90 | -1.23 | -1.37 | -1.33 | -1.20 |
| Normalized Diluted EPS | -0.53 | -0.74 | -0.82 | -0.80 | -0.74 |
| Average Basic Shares Outstanding | 61.18M | 51.00M | 43.16M | 38.12M | 35.92M |
| Average Diluted Shares Outstanding | 61.18M | 51.00M | 43.16M | 38.12M | 35.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |